Exact Mass: 493.3111
Exact Mass Matches: 493.3111
Found 500 metabolites which its exact mass value is equals to given mass value 493.3111
,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Tiamulin
D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents C254 - Anti-Infective Agent > C258 - Antibiotic Same as: D06127 CONFIDENCE standard compound; INTERNAL_ID 1055
Syringolin A
A syrbactin that has a (3E,9E)-2,7-dioxo-1,6-diazacyclododeca-3,9-diene skeleton that is substituted by an isopropyl group at position 5 and by a [(2S)-2-({[(1S)-1-carboxy-2-methylpropyl]carbamoyl}amino)-3-methylbutanoyl]nitrilo group at the 8-pro-S position. It is produced by the pathogenic bacterium Pseudomonas syringae pv. syringae.
LysoPC(16:1(9Z)/0:0)
LysoPC(16:1(9Z)) is a lysophospholipid (LyP). It is a monoglycerophospholipid in which a phosphorylcholine moiety occupies a glycerol substitution site. Lysophosphatidylcholines can have different combinations of fatty acids of varying lengths and saturation attached at the C-1 (sn-1) position. Fatty acids containing 16, 18 and 20 carbons are the most common. LysoPC(16:1(9Z)), in particular, consists of one chain of palmitoleic acid at the C-1 position. The palmitoleic acid moiety is derived from animal fats and vegetable oils. Lysophosphatidylcholine is found in small amounts in most tissues. It is formed by hydrolysis of phosphatidylcholine by the enzyme phospholipase A2, as part of the de-acylation/re-acylation cycle that controls its overall molecular species composition. It can also be formed inadvertently during extraction of lipids from tissues if the phospholipase is activated by careless handling. In blood plasma significant amounts of lysophosphatidylcholine are formed by a specific enzyme system, lecithin:cholesterol acyltransferase (LCAT), which is secreted from the liver. The enzyme catalyzes the transfer of the fatty acids of position sn-2 of phosphatidylcholine to the free cholesterol in plasma, with formation of cholesterol esters and lysophosphatidylcholine. Lysophospholipids have a role in lipid signaling by acting on lysophospholipid receptors (LPL-R). LPL-Rs are members of the G protein-coupled receptor family of integral membrane proteins. [HMDB] LysoPC(16:1(9Z)/0:0) is a lysophospholipid (LyP). It is a monoglycerophospholipid in which a phosphorylcholine moiety occupies a glycerol substitution site. Lysophosphatidylcholines can have different combinations of fatty acids of varying lengths and saturation attached at the C-1 (sn-1) position. Fatty acids containing 16, 18 and 20 carbons are the most common. LysoPC(16:1(9Z)/0:0), in particular, consists of one chain of palmitoleic acid at the C-1 position. The palmitoleic acid moiety is derived from animal fats and vegetable oils. Lysophosphatidylcholine is found in small amounts in most tissues. It is formed by hydrolysis of phosphatidylcholine by the enzyme phospholipase A2, as part of the de-acylation/re-acylation cycle that controls its overall molecular species composition. It can also be formed inadvertently during extraction of lipids from tissues if the phospholipase is activated by careless handling. In blood plasma significant amounts of lysophosphatidylcholine are formed by a specific enzyme system, lecithin:cholesterol acyltransferase (LCAT), which is secreted from the liver. The enzyme catalyzes the transfer of the fatty acids of position sn-2 of phosphatidylcholine to the free cholesterol in plasma, with formation of cholesterol esters and lysophosphatidylcholine. Lysophospholipids have a role in lipid signaling by acting on lysophospholipid receptors (LPL-R). LPL-Rs are members of the G protein-coupled receptor family of integral membrane proteins.
Cytochalasin Npho
Cytochalasin Npho is a mycotoxin from Phomopsis sp Mycotoxin from Phomopsis species
(5Z)-7-[(1R,2R,5S)-5-Hydroxy-2-[(1E,3S,5Z)-3-hydroxyocta-1,5-dien-1-yl]-3-oxocyclopentyl]hept-5-enoylcarnitine
(5Z)-7-[(1R,2R,5S)-5-hydroxy-2-[(1E,3S,5Z)-3-hydroxyocta-1,5-dien-1-yl]-3-oxocyclopentyl]hept-5-enoylcarnitine is an acylcarnitine. More specifically, it is an (5Z)-7-[(1R,2R,5S)-5-hydroxy-2-[(1E,3S,5Z)-3-hydroxyocta-1,5-dien-1-yl]-3-oxocyclopentyl]hept-5-enoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (5Z)-7-[(1R,2R,5S)-5-hydroxy-2-[(1E,3S,5Z)-3-hydroxyocta-1,5-dien-1-yl]-3-oxocyclopentyl]hept-5-enoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine (5Z)-7-[(1R,2R,5S)-5-hydroxy-2-[(1E,3S,5Z)-3-hydroxyocta-1,5-dien-1-yl]-3-oxocyclopentyl]hept-5-enoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
Chenodeoxycholylthreonine
Chenodeoxycholylthreonine belongs to a class of molecules known as bile acid-amino acid conjugates. These are bile acid conjugates that consist of a primary bile acid such as cholic acid, doxycholic acid and chenodeoxycholic acid, conjugated to an amino acid. Chenodeoxycholylthreonine consists of the bile acid chenodeoxycholic acid conjugated to the amino acid Threonine conjugated at the C24 acyl site.Bile acids play an important role in regulating various physiological systems, such as fat digestion, cholesterol metabolism, vitamin absorption, liver function, and enterohepatic circulation through their combined signaling, detergent, and antimicrobial mechanisms (PMID: 34127070). Bile acids also act as detergents in the gut and support the absorption of fats through the intestinal membrane. These same properties allow for the disruption of bacterial membranes, thereby allowing them to serve a bacteriocidal or bacteriostatic function. In humans (and other mammals) bile acids are normally conjugated with the amino acids glycine and taurine by the liver. This conjugation catalyzed by two liver enzymes, bile acid CoA ligase (BAL) and bile acid CoA: amino acid N-acyltransferase (BAT). Glycine and taurine bound BAs are also referred to as bile salts due to their decreased pKa and complete ionization resulting in these compounds being present as anions in vivo. Unlike glycine and taurine-conjugated bile acids, these recently discovered bile acids, such as Chenodeoxycholylthreonine, are produced by the gut microbiota, making them secondary bile acids (PMID: 32103176) or microbially conjugated bile acids (MCBAs) (PMID: 34127070). Evidence suggests that these bile acid-amino acid conjugates are produced by microbes belonging to Clostridia species (PMID: 32103176). These unusual bile acid-amino acid conjugates are found in higher frequency in patients with inflammatory bowel disease (IBD), cystic fibrosis (CF) and in infants (PMID: 32103176). Chenodeoxycholylthreonine appears to act as an agonist for the farnesoid X receptor (FXR) and it can also lead to reduced expression of bile acid synthesis genes (PMID: 32103176). It currently appears that microbially conjugated bile acids (MCBAs) or amino acid-bile acid conjugates are only conjugated to cholic acid, deoxycholic acid and chenodeoxycholic acid (PMID: 34127070). It has been estimated that if microbial conjugation of bile acids is very promiscuous and occurs for all potential oxidized, epimerized, and dehydroxylated states of each hydroxyl group present on cholic acid (C3, C7, C12) in addition to ring orientation, the total number of potential human bile acid conjugates could be over 2800 (PMID: 34127070).
Deoxycholylthreonine
Deoxycholylthreonine belongs to a class of molecules known as bile acid-amino acid conjugates. These are bile acid conjugates that consist of a primary bile acid such as cholic acid, doxycholic acid and chenodeoxycholic acid, conjugated to an amino acid. Deoxycholylthreonine consists of the bile acid deoxycholic acid conjugated to the amino acid Threonine conjugated at the C24 acyl site.Bile acids play an important role in regulating various physiological systems, such as fat digestion, cholesterol metabolism, vitamin absorption, liver function, and enterohepatic circulation through their combined signaling, detergent, and antimicrobial mechanisms (PMID: 34127070). Bile acids also act as detergents in the gut and support the absorption of fats through the intestinal membrane. These same properties allow for the disruption of bacterial membranes, thereby allowing them to serve a bacteriocidal or bacteriostatic function. In humans (and other mammals) bile acids are normally conjugated with the amino acids glycine and taurine by the liver. This conjugation catalyzed by two liver enzymes, bile acid CoA ligase (BAL) and bile acid CoA: amino acid N-acyltransferase (BAT). Glycine and taurine bound BAs are also referred to as bile salts due to their decreased pKa and complete ionization resulting in these compounds being present as anions in vivo. Unlike glycine and taurine-conjugated bile acids, these recently discovered bile acids, such as Deoxycholylthreonine, are produced by the gut microbiota, making them secondary bile acids (PMID: 32103176) or microbially conjugated bile acids (MCBAs) (PMID: 34127070). Evidence suggests that these bile acid-amino acid conjugates are produced by microbes belonging to Clostridia species (PMID: 32103176). These unusual bile acid-amino acid conjugates are found in higher frequency in patients with inflammatory bowel disease (IBD), cystic fibrosis (CF) and in infants (PMID: 32103176). Deoxycholylthreonine appears to act as an agonist for the farnesoid X receptor (FXR) and it can also lead to reduced expression of bile acid synthesis genes (PMID: 32103176). It currently appears that microbially conjugated bile acids (MCBAs) or amino acid-bile acid conjugates are only conjugated to cholic acid, deoxycholic acid and chenodeoxycholic acid (PMID: 34127070). It has been estimated that if microbial conjugation of bile acids is very promiscuous and occurs for all potential oxidized, epimerized, and dehydroxylated states of each hydroxyl group present on cholic acid (C3, C7, C12) in addition to ring orientation, the total number of potential human bile acid conjugates could be over 2800 (PMID: 34127070).
1-(9Z-Nonadecenoyl)-glycero-3-phosphoethanolamine
(2R)-2-{[(9Z)-Hexadec-9-enoyl]oxy}-3-hydroxypropyl 2-(trimethylazaniumyl)ethyl phosphate
4-[[2-Methyl-2-[4-[5-(trifluoromethyl)pyridin-2-yl]piperazin-1-yl]propanoyl]amino]adamantane-1-carboxamide
N(4)-Oleylcytosine arabinoside
[(2R,3S,4S,6R,7S,8R)-4-Ethenyl-3-hydroxy-2,4,7,14-tetramethyl-9-oxo-6-tricyclo[5.4.3.01,8]tetradecanyl] 2-[2-(diethylamino)ethylsulfanyl]acetate
Glycolipids
Glycolipids is practically insoluble (in water) and a moderately acidic compound (based on its pKa). Glycolipids can be found in chayote, chinese mustard, swamp cabbage, and winter squash, which makes glycolipids a potential biomarker for the consumption of these food products. Glycolipids are lipids with a carbohydrate attached by a glycosidic bond. Their role is to maintain the stability of the cell membrane and to facilitate cellular recognition, which is crucial to the immune response and in the connections that allow cells to connect to one another to form tissues. Glycolipids are found on the surface of all eukaryotic cell membranes, where they extend from the phospholipid bilayer into the extracellular environment .
Vinylamycin
A 15-membered cyclodepsipeptide isolated from Streptomyces sp.M1982-63F1. It exhibits moderate activity against Gram-positive bacteria.
INDANOMYCIN
An indene that is (3aS,7aR)-2,3,3a,4,5,7a-hexahydro-1H-indene which is substituted at the 2-pro-R position by a 1H-pyrrol-2-ylcarbonyl group, at the 9-pro-S position by an ethyl group, and at the 5-pro-R position by a hexa-1,3-dineyl group in which position 4 has been substituted by a (2R,3S,6R)-6-[(1R)-1-carboxyethyl]-3-methyltetrahydropyran-2-yl group. It exhibits activity against Gram-positive bacteria as well as antihypertensive and antitumour. It also functions as an effective growth promoter for ruminants.
Ala Phe Arg Thr
Ala Phe Thr Arg
Ala Ile Lys Tyr
Ala Ile Tyr Lys
Ala Lys Ile Tyr
Ala Lys Leu Tyr
Ala Lys Tyr Ile
Ala Lys Tyr Leu
Ala Leu Lys Tyr
Ala Leu Tyr Lys
Ala Arg Phe Thr
Ala Arg Thr Phe
Ala Thr Phe Arg
Ala Thr Arg Phe
Ala Tyr Ile Lys
Ala Tyr Lys Ile
Ala Tyr Lys Leu
Ala Tyr Leu Lys
Phe Ala Arg Thr
Phe Ala Thr Arg
Phe Ile Lys Ser
Phe Ile Ser Lys
Phe Lys Ile Ser
Phe Lys Leu Ser
Phe Lys Ser Ile
Phe Lys Ser Leu
Phe Lys Thr Val
Phe Lys Val Thr
Phe Leu Lys Ser
Phe Leu Ser Lys
Phe Arg Ala Thr
Phe Arg Thr Ala
Phe Ser Ile Lys
Phe Ser Lys Ile
Phe Ser Lys Leu
Phe Ser Leu Lys
Phe Thr Ala Arg
Phe Thr Lys Val
Phe Thr Arg Ala
Phe Thr Val Lys
Phe Val Lys Thr
Phe Val Thr Lys
Gly Arg Val Tyr
Gly Arg Tyr Val
Gly Val Arg Tyr
Gly Val Tyr Arg
Gly Tyr Arg Val
Gly Tyr Val Arg
His Ile Lys Pro
His Ile Pro Lys
His Ile Pro Gln
His Ile Gln Pro
His Lys Ile Pro
His Lys Leu Pro
His Lys Pro Ile
His Lys Pro Leu
His Leu Lys Pro
His Leu Pro Lys
His Leu Pro Gln
His Leu Gln Pro
His Pro Ile Lys
His Pro Ile Gln
His Pro Lys Ile
His Pro Lys Leu
His Pro Leu Lys
His Pro Leu Gln
His Pro Gln Ile
His Pro Gln Leu
His Gln Ile Pro
His Gln Leu Pro
His Gln Pro Ile
His Gln Pro Leu
Ile Ala Lys Tyr
Ile Ala Tyr Lys
Ile Phe Lys Ser
Ile Phe Ser Lys
Ile His Lys Pro
Ile His Pro Lys
Ile His Pro Gln
Ile His Gln Pro
Ile Lys Ala Tyr
Ile Lys Phe Ser
Ile Lys His Pro
Ile Lys Pro His
Ile Lys Ser Phe
Ile Lys Tyr Ala
Ile Pro His Lys
Ile Pro His Gln
Ile Pro Lys His
Ile Pro Gln His
Ile Gln His Pro
Ile Gln Pro His
Ile Ser Phe Lys
Ile Ser Lys Phe
Ile Tyr Ala Lys
Ile Tyr Lys Ala
Lys Ala Ile Tyr
Lys Ala Leu Tyr
Lys Ala Tyr Ile
Lys Ala Tyr Leu
Lys Phe Ile Ser
Lys Phe Leu Ser
Lys Phe Ser Ile
Lys Phe Ser Leu
Lys Phe Thr Val
Lys Phe Val Thr
Lys His Ile Pro
Lys His Leu Pro
Lys His Pro Ile
Lys His Pro Leu
Lys Ile Ala Tyr
Lys Ile Phe Ser
Lys Ile His Pro
Lys Ile Pro His
Lys Ile Ser Phe
Lys Ile Tyr Ala
Lys Leu Ala Tyr
Lys Leu Phe Ser
Lys Leu His Pro
Lys Leu Pro His
Lys Leu Ser Phe
Lys Leu Tyr Ala
Lys Pro His Ile
Lys Pro His Leu
Lys Pro Ile His
Lys Pro Leu His
Lys Ser Phe Ile
Lys Ser Phe Leu
Lys Ser Ile Phe
Lys Ser Leu Phe
Lys Thr Phe Val
Lys Thr Val Phe
Lys Val Phe Thr
Lys Val Thr Phe
Lys Tyr Ala Ile
Lys Tyr Ala Leu
Lys Tyr Ile Ala
Lys Tyr Leu Ala
Leu Ala Lys Tyr
Leu Ala Tyr Lys
Leu Phe Lys Ser
Leu Phe Ser Lys
Leu His Lys Pro
Leu His Pro Lys
Leu His Pro Gln
Leu His Gln Pro
Leu Lys Ala Tyr
Leu Lys Phe Ser
Leu Lys His Pro
Leu Lys Pro His
Leu Lys Ser Phe
Leu Lys Tyr Ala
Leu Pro His Lys
Leu Pro His Gln
Leu Pro Lys His
Leu Pro Gln His
Leu Gln His Pro
Leu Gln Pro His
Leu Ser Phe Lys
Leu Ser Lys Phe
Leu Tyr Ala Lys
Leu Tyr Lys Ala
Pro His Ile Lys
Pro His Ile Gln
Pro His Lys Ile
Pro His Lys Leu
Pro His Leu Lys
Pro His Leu Gln
Pro His Gln Ile
Pro His Gln Leu
Pro Ile His Lys
Pro Ile His Gln
Pro Ile Lys His
Pro Ile Gln His
Pro Lys His Ile
Pro Lys His Leu
Pro Lys Ile His
Pro Lys Leu His
Pro Leu His Lys
Pro Leu His Gln
Pro Leu Lys His
Pro Leu Gln His
Pro Gln His Ile
Ser Phe Ile Lys
Ser Phe Lys Ile
Ser Phe Lys Leu
Ser Phe Leu Lys
Ser Ile Phe Lys
Ser Ile Lys Phe
Ser Lys Phe Ile
Ser Lys Phe Leu
Ser Lys Ile Phe
Ser Lys Leu Phe
Ser Leu Phe Lys
Ser Leu Lys Phe
Thr Phe Lys Val
Thr Phe Val Lys
Thr Lys Phe Val
Thr Lys Val Phe
Thr Val Phe Lys
Thr Val Lys Phe
Val Phe Lys Thr
Val Phe Thr Lys
Val Lys Phe Thr
Val Lys Thr Phe
Val Thr Phe Lys
Val Thr Lys Phe
Tyr Ala Ile Lys
Tyr Ala Lys Ile
Tyr Ala Lys Leu
Tyr Ala Leu Lys
Tyr Ile Ala Lys
Tyr Ile Lys Ala
Tyr Lys Ala Ile
Tyr Lys Ala Leu
Tyr Lys Ile Ala
Tyr Lys Leu Ala
Tyr Leu Ala Lys
Tyr Leu Lys Ala
PC(16:1/0:0)
PC(16:1/0:0)[U]
PC(P-17:0/0:0)
LysoPC(16:1/0:0)
Cytochalasin Npho
1-[(9E)-hexadecenoyl]-sn-glycero-3-phosphocholine
A lysophosphatidylcholine 16:1 in which the 1-acyl group is (9E)-hexadecenoyl.
[2-[(E)-hexadec-9-enoyl]oxy-3-hydroxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
(5Z)-7-[(1R,2R,5S)-5-Hydroxy-2-[(1E,3S,5Z)-3-hydroxyocta-1,5-dien-1-yl]-3-oxocyclopentyl]hept-5-enoylcarnitine
[3-[2-aminoethoxy(hydroxy)phosphoryl]oxy-2-hydroxypropyl] (E)-nonadec-9-enoate
1-[3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-4-[[(E)-octadec-9-enyl]amino]pyrimidin-2-one
[3-[(E)-hexadec-9-enoyl]oxy-2-hydroxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
(2R)-2-{[(9Z)-Hexadec-9-enoyl]oxy}-3-hydroxypropyl 2-(trimethylazaniumyl)ethyl phosphate
(2R)-N-[[(10S,11S)-13-[(2R)-1-hydroxypropan-2-yl]-11-methyl-14-oxo-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-10-yl]methyl]-N,1-dimethylpyrrolidine-2-carboxamide
(1R,9S,10S,11S)-12-[2-(dimethylamino)acetyl]-10-(hydroxymethyl)-11-(4-methylpiperazine-1-carbonyl)-5-phenyl-7,12-diazatricyclo[7.2.1.02,7]dodeca-2,4-dien-6-one
(2R)-N-[[(10S,11S)-13-[(2S)-1-hydroxypropan-2-yl]-11-methyl-14-oxo-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-10-yl]methyl]-N,1-dimethylpyrrolidine-2-carboxamide
(2R)-N-[[(10R,11S)-13-[(2R)-1-hydroxypropan-2-yl]-11-methyl-14-oxo-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-10-yl]methyl]-N,1-dimethylpyrrolidine-2-carboxamide
(2S)-N-[[(10S,11R)-13-[(2S)-1-hydroxypropan-2-yl]-11-methyl-14-oxo-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-10-yl]methyl]-N,1-dimethylpyrrolidine-2-carboxamide
(2R)-N-[[(10R,11S)-13-[(2S)-1-hydroxypropan-2-yl]-11-methyl-14-oxo-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-10-yl]methyl]-N,1-dimethylpyrrolidine-2-carboxamide
(2S)-N-[[(10R,11S)-13-[(2S)-1-hydroxypropan-2-yl]-11-methyl-14-oxo-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-10-yl]methyl]-N,1-dimethylpyrrolidine-2-carboxamide
(2S)-N-[[(10R,11R)-13-[(2S)-1-hydroxypropan-2-yl]-11-methyl-14-oxo-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-10-yl]methyl]-N,1-dimethylpyrrolidine-2-carboxamide
N-[(2S,3R)-2-[[cyclopropylmethyl(methyl)amino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-2-phenylacetamide
(2R,3S)-2-[[cyclopentylmethyl(methyl)amino]methyl]-8-[2-(3-fluorophenyl)ethynyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-6-one
N-[(4S,7R,8R)-5-(cyclopropylmethyl)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-2-phenylacetamide
N-[(4R,7R,8R)-8-methoxy-4,7,10-trimethyl-11-oxo-5-(2-phenylethyl)-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclopropanecarboxamide
N-[(4S,7S,8R)-8-methoxy-4,7,10-trimethyl-11-oxo-5-(2-phenylethyl)-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclopropanecarboxamide
N-[(4S,7R,8S)-8-methoxy-4,7,10-trimethyl-11-oxo-5-(2-phenylethyl)-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclopropanecarboxamide
(2S)-N-[[(10S,11S)-13-[(2S)-1-hydroxypropan-2-yl]-11-methyl-14-oxo-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-10-yl]methyl]-N,1-dimethylpyrrolidine-2-carboxamide
(2R)-N-[[(10S,11R)-13-[(2R)-1-hydroxypropan-2-yl]-11-methyl-14-oxo-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-10-yl]methyl]-N,1-dimethylpyrrolidine-2-carboxamide
N-[(2R,3S)-2-[[cyclopropylmethyl(methyl)amino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-2-phenylacetamide
N-[(2R,3R)-2-[[cyclopropylmethyl(methyl)amino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-2-phenylacetamide
N-[(2R,3R)-2-[[cyclopropylmethyl(methyl)amino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-2-phenylacetamide
N-[(4R,7R,8S)-5-(cyclopropylmethyl)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-2-phenylacetamide
N-[(4R,7S,8R)-5-(cyclopropylmethyl)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-2-phenylacetamide
N-[(4S,7R,8S)-5-(cyclopropylmethyl)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-2-phenylacetamide
N-[(4R,7R,8R)-5-(cyclopropylmethyl)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-2-phenylacetamide
N-[(4S,7S,8R)-5-(cyclopropylmethyl)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-2-phenylacetamide
N-[(4S,7S,8S)-5-(cyclopropylmethyl)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-2-phenylacetamide
N-[(4R,7S,8S)-5-(cyclopropylmethyl)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-2-phenylacetamide
N-[(4S,7S,8S)-8-methoxy-4,7,10-trimethyl-11-oxo-5-(2-phenylethyl)-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclopropanecarboxamide
N-[(4S,7R,8R)-8-methoxy-4,7,10-trimethyl-11-oxo-5-(2-phenylethyl)-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclopropanecarboxamide
N-[(4R,7S,8S)-8-methoxy-4,7,10-trimethyl-11-oxo-5-(2-phenylethyl)-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclopropanecarboxamide
N-[(4R,7S,8R)-8-methoxy-4,7,10-trimethyl-11-oxo-5-(2-phenylethyl)-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclopropanecarboxamide
(2S)-N-[[(10S,11R)-13-[(2R)-1-hydroxypropan-2-yl]-11-methyl-14-oxo-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-10-yl]methyl]-N,1-dimethylpyrrolidine-2-carboxamide
(1S,9R,10R,11R)-12-[2-(dimethylamino)acetyl]-10-(hydroxymethyl)-11-(4-methylpiperazine-1-carbonyl)-5-phenyl-7,12-diazatricyclo[7.2.1.02,7]dodeca-2,4-dien-6-one
(2R)-N-[[(10R,11R)-13-[(2S)-1-hydroxypropan-2-yl]-11-methyl-14-oxo-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-10-yl]methyl]-N,1-dimethylpyrrolidine-2-carboxamide
(2S)-N-[[(10R,11R)-13-[(2R)-1-hydroxypropan-2-yl]-11-methyl-14-oxo-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-10-yl]methyl]-N,1-dimethylpyrrolidine-2-carboxamide
(2R)-N-[[(10R,11R)-13-[(2R)-1-hydroxypropan-2-yl]-11-methyl-14-oxo-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-10-yl]methyl]-N,1-dimethylpyrrolidine-2-carboxamide
N-[(2S,3S,4R)-3,4-dihydroxy-15-methyl-1-[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhexadecan-2-yl]formamide
[3-[(Z)-heptadec-9-enoxy]-2-hydroxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
2-aminoethyl [2-hydroxy-3-[(Z)-icos-11-enoxy]propyl] hydrogen phosphate
[3-[2-aminoethoxy(hydroxy)phosphoryl]oxy-2-hydroxypropyl] (Z)-nonadec-9-enoate
[2-propanoyloxy-3-[(Z)-tridec-9-enoxy]propyl] 2-(trimethylazaniumyl)ethyl phosphate
3-Hydroxy-2-(2-hydroxytetradecanoylamino)undecane-1-sulfonic acid
3-Hydroxy-2-(2-hydroxypentadecanoylamino)decane-1-sulfonic acid
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(Z)-heptadec-9-enoxy]propan-2-yl] acetate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(Z)-pentadec-9-enoxy]propan-2-yl] butanoate
3-Hydroxy-2-(2-hydroxytridecanoylamino)dodecane-1-sulfonic acid
3-Hydroxy-2-(2-hydroxydodecanoylamino)tridecane-1-sulfonic acid
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(Z)-tridec-9-enoxy]propan-2-yl] hexanoate
[3-[(Z)-hexadec-9-enoyl]oxy-2-hydroxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
2-[hydroxy-[(E)-3-hydroxy-2-(octanoylamino)undec-4-enoxy]phosphoryl]oxyethyl-trimethylazanium
[2-acetyloxy-3-[(Z)-tetradec-9-enoxy]propyl] 2-(trimethylazaniumyl)ethyl phosphate
[3-acetyloxy-2-[(Z)-tridec-9-enoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(Z)-hexadec-9-enoxy]propan-2-yl] propanoate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(Z)-tetradec-9-enoxy]propan-2-yl] pentanoate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-butanoyloxypropan-2-yl] (Z)-tetradec-9-enoate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-propanoyloxypropan-2-yl] (Z)-pentadec-9-enoate
[1-acetyloxy-3-[2-aminoethoxy(hydroxy)phosphoryl]oxypropan-2-yl] (Z)-hexadec-9-enoate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-pentanoyloxypropan-2-yl] (Z)-tridec-9-enoate
2-aminoethyl [(2R)-2-hydroxy-3-[(E)-icos-1-enoxy]propyl] hydrogen phosphate
[(2R)-3-[(E)-hexadec-7-enoyl]oxy-2-hydroxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
2-[hydroxy-[(E)-3-hydroxy-2-(propanoylamino)hexadec-4-enoxy]phosphoryl]oxyethyl-trimethylazanium
2-[[(E)-2-acetamido-3-hydroxyheptadec-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[(E)-3-hydroxy-2-(pentanoylamino)tetradec-4-enoxy]phosphoryl]oxyethyl-trimethylazanium
2-[[(E)-2-(butanoylamino)-3-hydroxypentadec-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[(E)-3-hydroxy-2-(undecanoylamino)oct-4-enoxy]phosphoryl]oxyethyl-trimethylazanium
2-[[(E)-2-(heptanoylamino)-3-hydroxydodec-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[[(E)-2-(decanoylamino)-3-hydroxynon-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[[(E)-2-(hexanoylamino)-3-hydroxytridec-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[(E)-3-hydroxy-2-(nonanoylamino)dec-4-enoxy]phosphoryl]oxyethyl-trimethylazanium
1-[(9Z)-hexadecenoyl]-sn-glycero-3-phosphocholine
A 1-O-acyl-sn-glycero-3-phosphocholine in which the 1-acyl group is (9Z)-hexadecenoyl (palmitoleoyl).
2-(3-(1-(((4E,10E)-2,9-Dioxo-12-isopropyl-1,8-diazacyclododecane-4,10-diene-3-yl)carbamoyl)-2-methylpropyl)ureido)-3-methylbutyric acid
2-[(9Z)-hexadecenoyl]-sn-glycero-3-phosphocholine
A lysophosphatidylcholine(0:0/16:1) in which the 2-acyl group is specified as (9Z)-hexadecenoyl.
[(9Z)-hexadecenoyl]-sn-glycero-3-phosphocholine
A lysophosphatidylcholine 16:1 in which the acyl group is specified as (9Z)-hexadecenoyl and is located at either position 1 or 2.
lysophosphatidylcholine 16:1
An lysophosphatidylcholine in which the acyl group is hexadecenoyl (position of double bond not specified). If R1 is hexadecenoyl and R2 is a hydrogen then the molecule is a 1-acyl-sn-glycero-3-phosphocholine. If R1 is a hydrogen and R2 is hexadecenoyl then the molecule is a 2-acyl-sn-glycero-3-phosphocholine.
lysophosphatidylcholine(0:0/16:1)
A 2-acyl-sn-glycero-3-phosphocholine in which the 2-acyl group contains 16 carbons and 1 double bond.
Lysophosphatidylcholine(16:1/0:0)
A 1-acyl-sn-glycero-3-phosphocholine in which the 1-acyl group contains 16 carbons and 1 double bond.
phosphatidylethanolamine 18:1 zwitterion
A 1,2-diacyl-sn-glycero-3-phosphoethanolamine zwitterion in which the two acyl groups contain a total of 18 carbons and 1 double bond.
phosphatidylcholine 15:1
A 1,2-diacyl-sn-glycero-3-phosphocholine in which the two acyl groups contain a total of 15 carbons and 1 double bond.
lysophosphatidylcholine (16:1/0:0)
A lysophosphatidylcholine 16:1 in which the acyl group is located at position 1.
PC(15:1)
Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved
LdMePE(18:1)
Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved
LdMePE(17:1)
Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved
PC(16:1)
Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved
5,8,13-trihydroxy-14-(1-hydroxy-4-methyldecan-3-yl)-3-isopropyl-6-methyl-11-methylidene-1-oxa-4,7,12-triazacyclotetradeca-4,7,9,12-tetraen-2-one
14-ethyl-2,6-dihydroxy-4,19-dimethoxy-16-methyl-9,11-dioxa-14-azaheptacyclo[10.7.2.1²,⁵.0¹,¹³.0³,⁸.0⁸,¹².0¹⁶,²⁰]docosan-21-yl acetate
(2r)-2-[(5s,6r)-6-[(3e,5e)-6-[(1s,4s,5r)-1-ethyl-4-(1h-pyrrole-2-carbonyl)-2,3,3a,4,5,7a-hexahydro-1h-inden-5-yl]hexa-3,5-dien-3-yl]-5-methyloxan-2-yl]propanoic acid
(1r,2s,3s,4s,5s,6r,8r,12r,13r,16r,19s,20s,21r)-14-ethyl-4,6,19,21-tetramethoxy-16-(methoxymethyl)-9,11-dioxa-14-azaheptacyclo[10.7.2.1²,⁵.0¹,¹³.0³,⁸.0⁸,¹².0¹⁶,²⁰]docosane
3-benzyl-1,6,12-trihydroxy-4,10,12-trimethyl-5-methylidene-3h,3ah,4h,6h,6ah,9h,10h,11h,15h-cycloundeca[d]isoindol-15-yl acetate
(3s,3ar,6s,6ar,10s,12r,15r,15ar)-3-benzyl-1,6,12-trihydroxy-4,5,10,12-tetramethyl-3h,3ah,6h,6ah,9h,10h,11h,15h-cycloundeca[d]isoindol-15-yl acetate
(2-{[(2r)-3-[(9z)-hexadec-9-enoyloxy]-2-hydroxypropyl phosphonato]oxy}ethyl)trimethylazanium
3beta-acetoxynorerythrosuamine
{"Ingredient_id": "HBIN008156","Ingredient_name": "3beta-acetoxynorerythrosuamine","Alias": "3\u03b2-acetoxynorerythrosuamine","Ingredient_formula": "C26H39NO8","Ingredient_Smile": "CC1C2C(CCC1=CC(=O)OCCNC)C3(CCC(C(C3C(=O)C2O)(C)C(=O)OC)OC(=O)C)C","Ingredient_weight": "493.6 g/mol","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "25340;265","TCMSP_id": "NA","TCM_ID_id": "8175;24321","PubChem_id": "101606278","DrugBank_id": "NA"}